Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

J Hematol Oncol · 2024 · PMC11157748 · PMID 38845015

Europe PMC DOI

hedged sentence

0.4600

closest p · 9.2× alpha

0.4600

boldest claim

The sentences

did not reach statistical significancep = 0.46not close (p > 0.1)

In a subgroup analysis restricted to the EMD and PSD cohorts, patients with EMD demonstrated numerically inferior OS [median OS 14.8 (95% CI: 9-NR)] compared to PSD [median OS 19.9 (95% CI: 14.1-NR), although this did not reach statistical significance ( p = 0.46).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.